Customer Letter Archive

Please note, the following Customer Letters, in electronic format, do not replace the print version that you receive from your local Canadian Blood Services site. The print version must be retained as your file copy.

Protect yourself! Download the latest version of Adobe Reader before you view or download PDFs online.

Download Adobe Reader free >>

---

2013 | 2012 | 2011 |2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003

2012

Letter #	Date	Title
2012-35	2012-12-20	Change to the Canadian Blood Services Tamper Indicator Device - BC & Yukon Hospitals Only
2012-34	2012-12-05	Information Only Release of the Circulars of Information October 2012 Version
2012-33	2012-10-04	Information Only Plasma Protein Products Packing Slip Reduction
2012-32	2012-08-07	Requisition for Blood Group Genotyping (Patient) Requisition for Antibody Investigation Requisition for Blood Group Genotyping (Patient) Requisition for Antibody investigation
2012-31	2012-07-30	INFORMATION ONLY Important Information Regarding the Introduction of Octaplasma™ (Solvent Detergent (S/D)Treated Human Plasma)
2012-30	2012-07-19	INFORMATION ONLY Factor VII Critical Supply Update RE: Factor VII Critical Supply Update
2012-29	2012-07-16	INFORMATION ONLY Notification on GAMMAGARD LIQUID 30g Lot LE12M055AB RE: Notification on GAMMAGARD LIQUID 30g Lot LE12M055AB
2012-28	2012-06-28	INFORMATION ONLY Changes to the Special Request Order Form and the Blood Component Order Form Blood Component Order Form Special Request Order Form (RBC)
2012-27	2012-06-27	INFORMATION ONLY Factor VII Critical Supply Notice RE: Factor VII Critical Supply Notice
2012-25	2012-06-14	INFORMATION ONLY Health Canada Endorsed Important Safety Information on HepaGam B® (Hepatitis B Immune Globulin {Human} Injection) NOTICE TO HOSPITALS Health Canada Endorsed Important Safety Information on HepaGam B® (Hepatitis B Immune Globulin [Human] Injection)
2012-24	2012-06-05	INFORMATION ONLY Canadian Blood Services’ London Site Move to Brampton Facility
2012-23	2012-06-04	INFORMATION ONLY Alburex®, Albumin (Human) Changes to Temperature Storage Alburex DCL storage
2012-22	2012-05-30	Information Only Health Canada Endorsed Important Safety Information on Privigen®, Immune Globulin Intravenous (Human) Health Canada Endorsed Important Safety Information on Privigen®, Immune Globulin Intravenous (Human)
2012-21	2012-05-24	INFORMATION ONLY Xyntha® Solofuse™ Introducing SOLOFUSE™, a new all-in-one delivery device for XYNTHA®
2012-17 Correction	2012-05-23	CORRECTION INFORMATION ONLY Important Information Regarding the Introduction of Octaplasma™ (Solvent Detergent (S/D)Treated Human Plasma)
2012-20	2012-05-17	Discontinuation of Routine Platelet Yield Testing of Apheresis Platelets Notification of Apheresis Platelet Yield
2012-19	2012-05-16	Circular of Information – Quality Control (QC) Criteria for Red Blood Cells LR SAGM added
2012-18	2012-05-14	Corporate Name Change for Wyeth & Extended Temperature Storage for BeneFIX® Coagulation Factor IX (Recombinant) SJ Canadian Blood Services Letter BenXYN Introducing the convenience of extended room temperature storage for BeneFIX
2012-17	2012-05-01	Important Information Regarding the Introduction of Octaplasma™ (Solvent Detergent (S/D)Treated Human Plasma) Important treatment advance in Transfusion Medicine – Octaplasma® is now available in Canada Attachment #1 - Solvent Detergent Plasma Request Form Attachment #2 - Hospital Solvent Detergent Plasma Disposition Report Attachment #3 - Octaplasma Labeling First 6 Lots Attachment #4 - Octaplasma Labeling Future Labels
2012-16	2012-05-01	Change to the Shell of the Canadian Blood Services Shipping Containers
2012-15	2012-04-30	Revised dates for moves of Hamilton and London sites to Brampton
2012-14	2012-04-18	Update to the Phenotype Labelling Bug on the Red Blood Cell Component
2012-13	2012-04-12	Recommendations for the Notification of Recipients of a Blood Component Recall
2012-12	2012-04-03	Important Information Regarding Availability of Immune Globulin Products for 2012-2013
2012-11	2012-03-12	Canadian Blood Services’ Hamilton Site Move to Brampton Facility
2012-10	2012-03-08	Changes to Plasma Protein Products Distributed by Canadian Blood Services COAGULATION FACTOR Comparison Table Important treatment advance in von Willebrand disease (VWD) care - wilate® is now approved in Canada for VWD patients. New Enhanced Reconstitution device for GAMMAGARD S/D wilate®, now available in convenient 500 IU and 1000 IU vials of both FVIII and VWF per vial ADVATE 2mL SWFI for 250IU and 500IU approved for distribution in Canada
2012-09	2012-03-07	IMPORTANT INFORMATION REGARDING PATIENT IgA/Anti-IgA TESTING REQUESTS PATIENT REQUEST FOR IgA/ANTI-IgA TESTING FORM
2012-08	2012-02-29	Recommendations for Use of Prothrombin Complex Concentrates
2012-07	2012-02-27	2011 Hospital Satisfaction Survey Summary
2012-06	2012-02-21	Expanded Use of the Consignee (Customer) Notification Form
2012-02 Correction	2012-01-30	CORRECTION INFORMATION ONLY Launch of Hizentra™ 20%, Subcutaneous Immune Globulin (Human)
2012-05	2012-01-26	Shipping Containers Utilized for RBC Shipments
2012-04	2012-01-25	Corporate Name Change for Talecris Biotherpeutics, Ltd & Redesigned Latex-free Stopper Grifols product stopper redesign to address complaints related to latex-free stoppers used in 100, 50 and 25 mL formats Canadian Blood Services Name Change Letter
2012-03	2012-01-23	Change in Distribution of Starches Part II
2012-02	2012-01-19	Launch of Hizentra™ 20%, Subcutaneous Immune Globulin (Human) Hizentra, 20%, Subcutaneous Immune Globulin (human), 20% solution for injection
2012-01	2012-01-09	Research Use of Blood Components

2011

Letter #	Date	Title
2011-37	2011-12-02	Donor Red Cell Phenotyping Labelling
2011-36	2011-11-29	New Process for Issuing and Labelling of Deglycerolized RBC’s with Incomplete Testing/Donor Assessment
2011-35	2011-11-28	Canadian Blood Services’ Toronto Site Move to Brampton Facility
2011-34	2011-11-21	IVIG-Associated Hemolysis
2011-33	2011-11-15	Revised Process for Emergency Release of Blood Components
2011-32	2011-10-20	FEIBA NF (Anti-Inhibitor Coagulant Complex, Vapor Heated, Nanofiltered) EXPANDED TEMPERATURE STORAGE of 2°C to 25°C FEIBA NF 1000U and 2500U formats now approved with expanded temperature storage of +2°C to +25°C
2011-31	2011-10-12	Discontinuation of the CP2D Plasma Circular of Information
2011-30	2011-09-26	Changes to Canadian Blood Services Operations Medical On-Call Schedule Starting Week of October 3, 2011
2011-29	2011-09-20	Changes to Plasma Protein Products Distributed by Canadian Blood Services IMPORTANT INFORMATION – 12 MONTHS ROOM TEMPERATURE STORAGE Introduction of the “Next Generation” Mix2VialTM into octaplex® Product Kits
2011-28	2011-09-19	Canadian Guidelines for the Uniform Labelling of Blood and Blood Components Using ISBT 128
2011-27	2011-09-12	Changes to Physician’s Request for Directed Donation and Directed Donation Utilization Forms Directed Donation Utilization Report Physician's Request for Directed Donation
2011-26	2011-08-25	WinRho® SDF Product Information Cangene Letter
2011-25	2011-08-25	Implementation of New Label Material
2011-24	2011-08-25	Updates to the Clinical Guide to Transfusion, New On-line Edition
2011-23	2011-08-16	Circular of Information – Quality Control (QC) Criteria for Pooled Platelets LR CPD
2011-22	2011-08-15	Release of Plasma Component Circulars of Information – Change in Storage of Thawed Plasma from 24 Hours to 120 Hours (5 Days)
2011-21	2011-08-08	2011 Hospital Satisfaction Survey Summary
2011-20	2011-08-02	Availability of Beriplex® P/N (Human prothrombin complex) Comparison Table Behring letter
2011-19	2011-07-18	Donor Red Cell Phenotyping
2011-18	2011-07-14	Discontinuation of Printing Platelet Yields on Apheresis Platelet Labels
2011-17	2011-06-30	Important Information Regarding Phenotype Labelling Bug Attachment
2011-16	2011-06-30	Important Information Regarding - Extended ISBT 128 Label Attachment
2011-15	2011-06-28	Change in Distribution of Starches
2011-14	2011-06-27	Washed Red Blood Cells With Extended Expiry, Implementation Delay
2010-23 Correction	2011-06--27	CORRECTION - Expiration Time for Thawed Plasma (24 Hours vs. 5 Days)
2011-12 Correction	2011-06-13	CORRECTION - Circular of Information – Quality Control (QC) Criteria for Pooled Platelets LR CPD
2011-13	2011-06-01	Talecris Stopper Redesign Project Talecris Letter
2011-12	2011-05-17	Circular of Information – Quality Control (QC) Criteria for Pooled Platelets LR CPD
2011-11	2011-05-03	New Label Material
2011-10	2011-04-14	Health Canada Endorsed Important Safety Information on Vivaglobin® Behring letter
2011-09	2011-04-14	Donor Testing Announcement - Transfer of Donor Testing from Halifax to Toronto (Distributed to Atlantic Canada Facilities only)
2011-08	2011-03-14	Change to Move Dates to the New Brampton Facility
2011-07	2011-03-09	Important Information Regarding Availability of Immune Globulin Products for 2011-2012
2011-06	2011-03-03	Release of the Circulars of Information February 2011 Version
2011-05	2011-02-28	FEIBA NF (Anti-Inhibitor Coagulant Complex, Vapor Heated and Nanofiltered) Replaces FEIBA VH Baxter letter
2011-04	2011-02-22	CBS to Begin Labelling IgA Deficient SAGM Red Blood Cell Components
2011-03	2011-02-14	Introduction of MPX Testing (including HBV DNA)
2011-02	2011-01-31	Canadian Blood Services Evaluation of Current Use of Shipping Containers – Further Information
2011-01	2011-01-17	New Site Codes for Brampton and Dartmouth Facilities

/\ Top

2010

Letter #	Date	Title
2010-43	2010-12-07	Gamunex® and IGIVnex® (Immune Globulin Intravenous [Human], 10%) Now Indicated for Subcutaneous (SC) Administration Attachment
2010-42	2010-12-01	F040275, Requisition for Antibody Investigation Attachment
2010-40	2010-11-30	Labels on Plasma Components
2010-41	2010-11-29	Maritime Facilities Redevelopment Project-Logistics Test Plan Information for New Brunswick Hospitals
2010-39	2010-11-10	Canadian Blood Services Evaluating Current Use of Shipping Containers
2010-38	2010-11-03	New Consignee Notification Form For Confirmatory / Supplementary Test Results Attachment
2010-37	2010-10-18	Hospital Satisfaction Survey Summary Attachment
2010-36	2010-10-12	Licensed Berinert® & Mix2Vial™Transfer Device Behring Letter Jul. 19, 2010 Behring Letter Oct. 7, 2010
2010-35	2010-10-12	Production Trial of New Label Material
2010-34	2010-09-27	NiaStase RT® Activated Recombinant Human Blood Coagulation Factor VII Room Temperature Stable Now Available Attachment
2010-33	2010-09-23	Gammagard Liquid: New Vial Size Attachment
2010-32	2010-09-22	Circular of Information for AS-3 RBC and CP2D Platelet Components
2010-31	2010-09-20	Implementation of Fenwal Collection Sets/Automated Production Method at Canadian Blood Services – Saskatchewan Further Information
2010-30	2010-09-09	Further Information to Pediatric Platelet Transfusions and the Discontinuation of the Production of CP2D Platelets LR in Saskatchewan
2010-29	2010-08-19	Implementation of Fenwal Collection Sets/Automated Production Method at Canadian Blood Services – Saskatchewan UPDATE
2010-28	2010-08-10	Additional TRALI Reduction Measures for Plasma
2010-27	2010-07-28	Minor Modification to RBC Storage Container – Edmonton Site
2010-26	2010-07-27	Chagas Disease Lookback Attachement
2010-25	2010-07-19	WinRho SDF Product Information Cangene Letter
2010-24	2010-07-14	Important Information Regarding Updates to End Label for Double Components and New Héma-Québec Product Codes Attachment 1 Attachment 2 Attachment 3
2010-23	2010-07-12	Expiration Time for Thawed Plasma (24 Hours vs. 5 Days)
2010-22	2010-07-05	Pediatric Platelet Transfusions and the Discontinuation of the Production of CP2D Platelets LR in Saskatchewan
2010-21	2010-06-29	Implementation of Fenwal Collection Sets/Automated Production Method at Canadian Blood Services – Saskatchewan Procedure for Spiking New Buffy Coat Blood Bags
2010-20	2010-06-28	Stability of Helixate® FS for Continuous Infusion Behring letter
2010-19	2010-06-09	CSL Behring’s Privigen® Shelf Life Extension Behring letter
2010-18	2010-06-09	NiaStase RT® Activated Recombinant Human Blood Coagulation Factor VII Room Temperature Stable is coming to Canada NiaStase letter
2010-17	2010-05-31	Packed Red Blood Cell Units from donors with Red Blood Cell Antibodies
2010-16	2010-05-27	Approved Use of BAXJECT II Hi-Flow Reconstitution Device with FEIBATM VH IMMUNO Baxter letter
2010-15	2010-05-18	Introducing a new choice for patients….the Kogenate® FS 3000 IU vial Bayer Letter
2010-14	2010-05-06	Implementation of Fenwal Collection Sets/Automated Production Method at Canadian Blood Services – Saskatchewan
2010-13	2010-05-03	Circular of Information – CBS to Begin Selective Testing for Trypanosoma cruzi (T. cruzi) or Chagas Disease
2010-12	2010-04-14	Important Information Regarding Availability of Immune Globulin Products for 2010-2011
2010-11	2010-04-14	Further Implementation of Fenwal Blood Storage bags at Canadian Blood Services – Winnipeg
2010-10	2010-04-13	Humate-P® Made from Canadian Plasma and New Surgery Indication Behring Letter FVIII/vWF Products Comparison Table
2010-09	2010-03-29	Further Information Regarding Primary TRALI Reduction Measures
2010-08	2010-03-29	Association of WinRho® SDF ((Rho (D) Immune Globulin (Human)) with Intravascular Hemolysis in the Treatment of Immune Thrombocytopenic Purpura (ITP) – Important New Prescribing Information Cangene letter
2010-07	2010-03-08	Further Implementation of Fenwal Blood Storage Bags at Canadian Blood Services – Hamilton
2010-06	2010-02-23	Further Implementation of Fenwal Blood Storage bags at Canadian Blood Services – Toronto
2010-05	2010-02-11	Further Implementation of Fenwal Blood Storage bags at Canadian Blood Services
2010-04	2010-02-08	HepaGam B® Cangene letter HepaGam B regulatory status update HBIg comparison table
2010-03	2010-01-28	Changes to Plasma Protein Products Distributed by Canadian Blood Services Reconstitution of Octaplex Behring letter
2010-02	2010-01-18	Further Implementation of Fenwal Blood Storage bags at Canadian Blood Services – North Eastern Ontario and Nunavut
2010-01	2010-01-18	Compatibility of Talecris Latex-Free 20 mm Stoppers with Various Spiking Devices Compatibility of Talecris latex-free 20 mm stoppers with various spiking devices

/\ Top

2009

Letter #	Date	Title
2009-29	2009-12-22	dvate® 3000 IU approved for distribution in Canada Baxter letter
2009-28	2009-12-08	Product Announcement: Xyntha™
2009-27	2009-12-01	Release of the Circulars of Information January 2009 Edition
2009-26	2009-12-07	Important Information Regarding ISBT 128 Donation Number Labels
2009-25	2009-10-26	Changes to Plasma Protein Products Distributed by Canadian Blood Services Cytogam® Shelf Life Extension CSL Behring's Haemocomplettan® P-Fibrinogen Concentrate
2009-24	2009-10-21	New TRALI Patient Data Form
2009-23	2009-10-19	Further Implementation of Fenwal Blood Storage bags at Canadian Blood Services
2009-22	2009-10-08	Privigen® Increased Infusion Speed Immune Globulin Comparison Table
2009-21	2009-10-05	Inventory Status Update and Pandemic Readiness
2009-20	2009-09-28	Minor Modification to RBC Storage Container
2009-19	2009-09-22	Important Information regarding the “Produced On” Date on CPD Platelets, Pooled, LR for Components
2009-18	2009-08-27	New sizes of frozen plasma storage cartons.
2009-12	2009-08-20	Important information regarding the 2004 Circular of Information
2009-17	2009-07-16	Changes to Plasma Protein Products Distributed by Canadian Blood Services Baxter letter New 2000 IU vial size and NIPRO Safe Touch PSV 25 gauge butterfly for Helixate® FS Vivaglobin® Immune Globulin Subcutaneous is now available in 3ml vials
2009-15	2009-06-18	Important Information Regarding ISBT 128 Implementation
2009-16	2009-06-17	Important Information Regarding Availability of Immune Globulin Products for 2009-2010
2009-07	2009-06-17	Important Information Regarding TRALI Reduction Measures
2009-09	2009-06-08	Important Information Regarding New Héma Québec Product Codes
2009-01	2009-05-25	Important Information Regarding Circulars of Information
2009-14	2009-05-19	Changes to Plasma Protein Products Distributed by Canadian Blood Services Octaplex letter Wyeth letter
2009-13	2009-05-14	Important Information Regarding ISBT128 Implementation
2009-11	2009-05-11	Information Regarding the Availability of the Visual Assessment Guide
2009-10	2009-03-31	Incompatibility of Talecris Latex-free Stoppers and FluVen Infusion Sets. Talecris letter
2009-08	2009-03-26	Important Information Regarding ISBT 128 Implementation Attachment
2009-06	2009-03-02	Changes to Plasma Protein Products Distributed by Canadian Blood Services. Gamunex IGIV/nex approved by Health Canada for CIDP Humate-P Storage at room temperature Special Access Programs (Health Canada)
2009-02	2009-02-15	Important Information Regarding IVIG-Associated Hemolysis
2009-05	2009-02-05	Updated Information Regarding the Availability of octaplex®
2009-04	2009-01-15	Availability of Vivaglobin® (Immune Globulin Subcutaneous [Human]) Immune Globulin Comparison Table Vivaglobin® available in January 2009 for Primary Immunodeficient patients throughout Canada
2009-03	2009-01-09	Launch of PrivigenTM A new liquid, 10%, IVIG product> CSL Behring plans to launch a new 10% IVIG in January 2009: Privigentm

/\ Top

2008

Letter #	Date	Title
2008-29	2008-01-09	Important Information Regarding Double Platelet Collections – Follow-up
2008-28	2008-11-17	Important Information Regarding ISBT 128 Sample Labels and Product Codes Attachments: 1, 2-1, 2-2, 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9
2008-27	2008-10-15	Introduction of Privigentm A new liquid, 10%, IVIG product IVIG Comparison Table 2009-09-24 CSL Behring plans to launch Privigentm
2008-23	2008-10-14	Discontinuing Distribution of Infusion Sets
2008-25	2008-09-26	Important information regarding double platelet collections
2008-24	2008-09-23	Availability of Synagis® (Palivizumab) 2008-2009
2008-26	2008-09-15	CORRECTION: Introduction of wilate® (Human coagulation factor VIII and human von Willebrand factor) Wilate Letter
2008-09	2008-08-11	Important Information Regarding a New Guideline for Investigation of Suspected Transfusion Transmitted Bacterial Contamination Available from the Public Health Agency of Canada
2008-22	2008-07-31	Important Information Regarding the Availability of octaplex®
2008-17	2008-07-24	Whole Blood Component Codes/Names Updates for the Buffy Coat Production Method
2008-21	2008-07-24	Changes to Recombinant Factor VIII & IX Products Distributed by Canadian Blood Services Baxter Letter Bayer Letter Wyeth Letter
2008-19	2008-07-21	Important information regarding reduction of SAGM red blood cell minimum volume cut-off
2008-20	2008-07-17	Changes to Products Distributed by Canadian Blood Services: 1. Gamunex®/IGIVnex™ - Latex-free stoppers 2. Alburex® 5 – Availability of 500 mL vial size Talecris Letter
2008-18	2008-06-20	Further Information Regarding Pre-1986/Post-1990 Hepatitis C Settlement Program Refer to customer letter 2008-02
2008-07	2008-06-02	Important Information Regarding Circulars of Information: CBS to Begin using West Nile Virus (WNV)Nucleic Acid Testing (NAT) Licensed Test Kits
2008-16	2008-05-15	Changes to Products Distributed by Canadian Blood Services: 1. Advate® - Ancillary kit improvements 2. Berinert® P - Storage at room temperature & Administration kit 3. WinRho® SDF - New liquid formulation Baxter Letter CSL Behring Letter Cangene Letter
2008-15	2008-05-07	Important Information Regarding Availbility of IVIG Products for 2008-2009
2008-12	2008-05-06	Important Information Regarding New Equipment for Apheresis Platelet Collections
2008-14	2008-04-21	Important Information Regarding: Availability of Health Canada Licensed CytoGam® CSL Behring Letter Products Table
2008-13	2008-04-15	Introduction of wilate® (Human coagulation factor VIII and human von Willebrand factor) Octapharma Letter Products Comparison Table
2008-06	2008-04-09	Important Information Regarding ISBT 128 Planned Implementation at Canadian Blood Services
2008-11	2008-04-09	Introduction of octaplex® (Human Prothrombin Complex) Octapharma Letter
2008-03	2008-04-07	Important Information Regarding Revisions to Blood Component and Blood Product Order Forms
2008-10	2008-03-27	Health Canada's Special Access Programme (SAP): New Request Forms
2008-08	2008-03-06	Recombinant Factor VIII Products Distributed by Canadian Blood Services
2008-02	2008-02-14	Important Information Regarding Pre-1986/Post-1990 Hepatitis C Settlement Program
2008-05	2008-02-06	Further Information Regarding Primary TRALI Reduction Measures
2008-04	2008-01-25	New Recall Manual - Hospital Follow-Up Customer Letter Notification Form
2008-01	2008-01-04	Important Information Regarding TRALI Laboratory Investigations TRALI Info Form For the latest version of this form, please go to www.transfusionmedicine.ca

/\ Top

2007

Letter #	Date	Title
2007-46	2007-12-17	Important Information Regarding: Completion of Recombinate Phase-out in Canada Baxter Letter
2007-11	2007-12-14	Manual Transformation Product Label
2007-01	2007-11-29	Important Information Regarding Notification of Component Recall/Withdrawal Form
2007-45	2007-11-28	Important Information Regarding Medical Director London Centre, Canadian Blood Services
2007-44	2007-11-28	Important Information Regarding CPDA-1 Divided Products
2007-34	2007-11-23	Important Information Regarding Platelets Apheresis, LR Product Update
2007-30	2007-11-23	Important Information Regarding the Release of the 2004 and 2005 Circulars of Information - Amendments for the new Platelets Apheresis, LR Transfusion Instructions Label
2007-43	2007-11-14	CORRECTION: Introduction of Voluven® Fresenius Kabi Pre-Letter Fresenius Kabi Letter re:Voluven®
2007-38	2007-10-30	Important Information Regarding BeneFIX® Wyeth Letter
2007-39	2007-10-29	Introduction of HepaGam BTM (Hepatitis B Immune Globulin (Human) Injection) HepaGam B Launch Package HBIg Comparison Table
2007-42	2007-10-23	Update on Canadian Blood Services' Organizational Structure
2007-41	2007-10-23	Update on Canadian Blood Services' Organizational Structure
2007-40	2007-10-23	Update on Canadian Blood Services' Organizational Structure
2007-37	2007-10-11	Important Information Regarding Humate P ® Humate P Letter
2007-36	2007-10-10	Important Information Regarding Advate® Notification of Advate® Packaging Changes
2007-35	2007-09-27	Update on Canadian Blood Services Inventory Levels
2007-33	2007-09-27	Availability of Synagis® (Palivizumab) Request Form
2007-32	2007-09-19	Introduction of Voluven® Fresenius Kabi Canada Letter - Deleted See Customer Letter #2007-43 for further details Comparison Table
2007-29	2007-08-23	Update on Canadian Blood Services Inventory Levels
2007-28	2007-08-23	Update on CytoGam® Distribution via the Special Access Programme (SAP) CytoGam® Update
2007-24	2007-08-14	ISBT 128 Implementation at Héma-Québec
2007-27	2007-08-13	Important Information Regarding Current Canadian Blood Services Inventory Levels
2007-19	2007-08-10	Important Information Regarding Availability of IVIG Products for 2007-2008 Clinician GGL Notification Letter IVIG Comparison Table
2007-15	2007-08-07	2005 Circular of Information for the Use of Human Blood and Blood Components - Booklet format for Buffy Coat Production Method
2007-25	2007-08-02	Important Information Regarding Primary TRALI Reduction Measures
2007-26	2007-07-27	Field Correction: Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized Humate-P
2007-18	2007-07-24	Important Information Regarding Change to ACD Fresh Frozen Plasma Apheresis Storage Bag
2007-23	2007-06-20	Important Information Regarding: Limited Availability of Albumin 25%
2007-21	2007-06-15	Important Information Regarding CytoGam® Requiring Temporary Special Access Programme (SAP) Authorization Letter from CSL Behring Canada Revised Special Access Programme (SAP) Products Table
2007-16	2007-05-08	Important Information Regarding Recombinate Antihemophilic Factor (Recombinant) (rAHF) Phase-out in Canada Baxter Letter
2007-14	2007-04-24	Important Information Regarding Infusion Rate Inconsistencies Found in the CytoGam® Product Monograph CSL Behring Letter - CytoGam
2007-13	2007-04-23	Introduction of New Pall Medical Red Cell Storage Bags Questionnaire
2007-12	2007-04-04	Corporate Name Change - CSL Behring Canada, Inc. and Revised Special Access Programme (SAP) Products Table CSL Behring Letter Special Access Programme
2007-03	2007-02-27	Further Reducing the Risk of Bacterial Contamination of Platelet Concentrates Reference Material 1 Reference Material 2
2007-09	2007-02-26	Important Information Regarding Availability of VariZIGTM [Varicella Zoster Immune Globulin (Human) Lyophilized and its Reconstitution
2007-08	2007-02-19	Revisions to the Plasma Proteins Order Form Sample: Plasma protein order form
2007-10	2007-02-16	Revised Donation and Pool Number Labels
2007-05	2007-02-12	Changes to Blood Component Storage Containers
2007-07	2007-02-08	Implementation of a NewInventory Management System for Plasma Protein Products
2007-04	2007-02-01	ISBT 128 Implementation
2007-06	2007-01-26	Important Information Regarding Intravenous Immune Globulin (IVIG): Demand & Supply Trends and Utilization Guidelines
2007-02	2007-01-08	Bacterial Detection Testing

/\ Top

2006

Letter #	Date	Title
2006-35	2006-12-20	Expiry Date Extension - Fibrogammin P, Human Plasma Coagulation Factor XIII Behring Letter
2006-29	2006-11-27	Calculation of the Check Digit - Donation Number Label and Pooled Number Label
2006-32	2006-10-20	Important Information Regarding: Limited Availability of Albumin 5%
2006-25	2006-10-05	Important Information Regarding the Availability of the 4th Edition of the "Clinical Guide to Transfusion"
2006-30	2006-10-02	Availability of Advate
2006-28	2006-09-29	Availability of Anti-RSV Immune Globulin Respiratory Syncytial Virus Prophylaxis Request Form
2006-27	2006-09-20	Important Information Regarding IGIVnex and Gamunex Talecris Letter
2006-22	2006-09-01	Revised Donation and Pool Number Labels
2006-09	2006-08-25	Component Name and Code - Fresh Frozen Plasma Apheresis
2006-26	2006-08-03	Introduction of Advate and phase-out of Recombinate Antihemophilic Factor: Baxter Notification 1.2 Mb Advate fact sheet 507 Kb
2006-05	2006-07-13	Update on Buffy Coat - Revised Implementation Plan and New Spiking Method
2006-17	2006-06-26	WinRhoR SDF Dosing Guidelines for Treatment of Immune Thrombocytopenic Purpura (ITP) Cangene Letter
2006-21	2006-06-21	Room Temperature Storage Requirements for KogenateR FS Supplied with BIO-SET Bayer Letter - Important Information
2006-16	2006-06-14	Blood Components and Blood Products Order Forms
2006-20	2006-06-12	Availability of IGIVnexTM (Immune Globulin Intravenous [Human] 10%) Talecris Letter Talecris Information Insert
2006-24	2006-06-07	Availability of IVIG Products for 2006-2007
2006-19	2006-05-26	Corporate Changes - Talecris Biotherapeutics
2006-18	2006-05-09	Introduction of IGIVnexTM (Immune Globulin Intravenous [Human] 10%)
	2006-04-28	IGIVnexTM and Mixing of Different Immune Globulin Intravenous (Human) Products, (Talecris)
	2006-04-20	Talecris Letter to Doctors: Introducing IGIVnexTM, (Talecris)
	2006-04-20	IGIVnexTM Fact Sheet: The Gamunex process with Canadian-donor plasma, (Talecris)
2006-01	2006-03-02	Important Information Regarding Hemofil M, Antihemophilic Factor (Human)(AHF), Method M, Monoclonal Purified
2006-01	2006-03-01	Removal of Hemofil M, plasma derived FVIII
2006-15	2006-02-17	Introduction of VariZIGTM (Varicella Zoster Globulin (Human)) Lyophilized (Powder for Injection) Formulation with Sterile Diluent
2006-08	2006-02-16	Hematocrit of SAGM Red Blood Cells, LR - Update from Edmonton Pilot
2006-15 Cangene	2006-02-15	Important Information – New Product Introduction, VariZIGTM (Varicella Zoster Immune Globulin (Human)) Lyophilized (Powder for Injection) Formulation with Sterile Diluent
2006-14	2006-02-09	Important Safety Information Regarding NiaStase® eptacog alfa (activated)
2006-14 Novo Nordisk	2006-02-08	Re: NiaStase® – U.S. Dear Healthcare Professional Letter
2006-14 FDA Letter	2005-11-23	Important Drug Warning
2006-13	2006-01-30	Important Safety Information Regarding WinRho® SDF ((Rho (D) Immune Globulin (Human))
2006-13 Cangene	2006-01-24	Health Canada Endorsed Important Safety Information on WinRho® SDF (Rho (D) Immune Globulin (Human))
2006-04	2006-01-12	Hospital Pandemic Planning Questionnaire
2006-03	2006-01-11	Baxter Products - Changes to the Lot Numbering Format
2006-03 Baxter	2006-01-04	RE: Changes to the Lot Numbering Format of Baxter Products

/\ Top

2005

Letter #

Date

Title

2005-42	2005-12-08	BIOLOGIC RECALL, URGENT – WinRho® SDF, Rh(D) Immune Globulin (Human) for Injection, 5,000 IU (1,000 µg) Lot #02404013 and #02404022
2005-42 Cangene	2005-12-08	Cangene Corporation issues BIOLOGIC RECALL
2005-42 Recall Lot #02404013	2005-12-08	Fractionated product recall/withdrawal customer reconciliation report
2005-42 Recall Lot #02404022	2005-12-08	Fractionated product recall/withdrawal customer reconciliation report
2005-40	2005-12-07	Expiry Date Extension – Fibrogammin® P, Human Plasma Coagulation Factor XIII
2005-40 ZLB Behring	2005-10-28	Fibrogammin® P, extended expiry date
2005-38	2005-11-25	Updated Plasma Product Manufacturer Contact Information
2005-33	2005-10-27	Introduction of BIO-SET Needle-less Reconstitution Set for Bayer Kogenate® FS (Antihemophilic Factor (Recombinant)) Formulated with Sucrose and Recommendation for Use of a Separate Injection Filter
2005-33 Bayer	2005-10-26	Introducing Kogenate® FS (Antihemophilic Factor (Recombinant)), Formulated with Sucrose, Supplied with BIO-SET Needle-less Reconstitution Set
2005-34	2005-10-21	Buffy Coat Production Method – Additional Product Testing Information
2005-31	2005-10-19	Important Information about GamunexTM Immune Globulin Intravenous (Human)
2005-31 (Talecris)	2005-10-19	Health Canada Endorsed Important Safety Information on Gamunex®
2005-32	2005-10-18	Corporate Name Change – ZLB Behring Canada Inc.
2005-35	2005-10-06	Availability of Anti-RSV Immune Globulin
2005-30	2005-09-27	Additional Information Pertaining to the Buffy Coat Production Method
2005-27	2005-09-12	Washed red blood cells during Buffy Coat Pilot
2005-20	2005-09-13	Important Information Regarding Buffy Coat Production Method – Circular of Information
2005-29	2005-08-25	Important Information Regarding the Availability of the 2004 Circular of Information for the Use of Human Blood and Blood Components
2005-28	2005-07-29	Ratification of the Agreement with Ontario Support Staff
2005-24	2005-08-02	Canadian Blood Services Plasma Products and Services
2005-26	2005-07-27	Update on Tentative Agreement Reached with Ontario Support Staff
2005-25	2005-07-18	Labour Disruption Averted – Tentative Agreement Reached with Support Staff/Union
2005-23	2005-07-11	Further Information Regarding Possible Labour Disruptions
2005-22	2005-07-08	Information Regarding Possible Labour Disruptions
2005-21	2005-07-08	Information Regarding Adverse Reaction (London Centre)
2005-19	2005-06-20	Recombinate – Changes to Lot Numbering Format
2005-03	2005-05-26	Buffy Coat Production Method
2005-18	2005-05-17	Planned Measures to Protect the Blood Supply from West Nile Virus (WNV) – 2005 Season
2005-15	2005-05-04	Important Information Regarding WinRho® SDF
2005-13	2005-03-30	Introduction of Donor Testing for Antibody to Hepatitis B Core Antigen (Anti-HBc)
2005-14	2005-03-22	CORRECTION: Important Information Regarding Fibrinogen Concentrate Special Access Programme (Health Canada): Table (2006-06-12)
2005-12	2005-03-21	Important Information Regarding Fibrinogen Concentrate
2005-10	2005-03-11	New Donation Number Label
2005-07	2005-03-14	Additional Component Names and Codes – Buffy Coat Production Method (Winnipeg)
2005-08	2005-03-07	ABO/Rh Labelling of Red Blood Cell Components
2005-04	2005-01-27	Component Names and Codes – Buffy Coat Production Method
2005-05 Table	2005-01-19	Updated Special Access Programme Table
2005-05	2005-01-19	Updated Special Access Programme
2005-01	2005-01-19	Important Information Regarding BeneFIX®
2005-06	2005-01-14	Canadian Blood Services Launches Transfusion Medicine Web Site
2005-02	2005-01-11	Important Information Regarding WinRho® SDF

/\ Top

2004

Letter #

Date

Title

2004-22	2004-12-08	Malaria Deferral - Dominican Republic
2004-21	2004-12-16	Health Canada Licensure of Humate-P
2004-20	2004-12-07	Kogenate FS with bar code labels
2004-17	2004-09-24	Availability of Anti-RSV Immune Globulins
2004-16	2004-08-05	CORRECTION: Update to Expiry Date Labelling on Plasma Protein Products
2004-13	2004-07-30	Update to Expiry Date Labelling on Plasma Protein Products
2004-15	2004-07-14	Manufacturing of Antihemophilic Factor (Porcine) - Hyate: C - Discontinued
2004-14	2004-07-08	Fast Facts - West Nile Virus and the Blood System
2004-12	2004-06-16	Bacterial Detection in Platelets Apheresis
2004-11 Table	2004-06-14	Special Access Programme (SAP) Table
2004-11	2004-06-14	Special Access Programme (Health Canada)
2004-03	2004-05-17	Canadian Blood Services to Begin Using HCV RNA and HIV-1 RNA Licensed Test Kits
2004-10	2004-04-30	Gammagard S/D - Changes to Lot Numbering Format
2004-09	2004-04-22	Information for Health Care Professionals with Respect to Plans to Further Protect the Blood Supply from West Nile Virus
2004-08	2004-04-29	Availability of IVIG Products for 2004-2005
2004-07	2004-04-15	Information Regarding Special Access Programme
2004-06	2004-03-12	Changes to Fractionated Product Recall/Withdrawal Procedure
2004-05	2004-02-25	Factor VII Concentrate TIM 4 Immuno - Labelled Potency Change
2004-02	2004-02-24	Minimizing the Risk of Bacterial Contamination of Cellular Blood Components
2004-04	2004-02-13	Recombinate, Antihemophilic Factor (Recombinant) (rAHF) - Changes to Diluent
2004-01	2004-01-12	Availability of GamunexTM (Immune Globulin Intravenous (Human))

/\ Top

2003

Letter #

Date

Title

2003-30	2003-12-11	Introduction of GamunexTM (Immune Globulin Intravenous (Human))
2003-28	2003-11-10	Supplemental Information
2003-27	2003-11-06	Recall of Sterile Water for Injection, U.S.P. Packaged with Humate®-P, (Antihemophilic Factor/von Willebrand Factor Complex (Human))
2003-26	2003-11-05	Quarantine of Humate®-P, (Antihemophilic Factor/von Willebrand Factor Complex (Human))

/\ Top